Respiratory syncytial virus—a comprehensive review
AT Borchers, C Chang, ME Gershwin… - Clinical reviews in allergy …, 2013 - Springer
Respiratory syncytial virus (RSV) is amongst the most important pathogenic infections of
childhood and is associated with significant morbidity and mortality. Although there have …
childhood and is associated with significant morbidity and mortality. Although there have …
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
T Andabaka, JW Nickerson… - … ‐Based Child Health …, 2013 - Wiley Online Library
Background Respiratory syncytial virus (RSV) is one of the most important viral pathogens
causing acute respiratory infections, resulting in about 3.4 million hospitalisations annually …
causing acute respiratory infections, resulting in about 3.4 million hospitalisations annually …
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
Committee on Infectious Diseases and Bronchiolitis … - …, 2014 - publications.aap.org
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection
MT Caserta, ST O'Leary, FM Munoz, SL Ralston - Pediatrics, 2023 - publications.aap.org
Guidance from the American Academy of Pediatrics (AAP) for the use of palivizumab
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement …
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a …
A Shoukat, E Abdollahi, AP Galvani… - The Lancet Regional …, 2023 - thelancet.com
Background The cost-effectiveness of immunisation strategies with a long-acting
monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for …
monoclonal antibody (nirsevimab) and/or a protein-based maternal vaccine (RSVpreF) for …
Cost-effectiveness of palivizumab for respiratory syncytial virus: a systematic review
S Mac, A Sumner, S Duchesne-Belanger, R Stirling… - …, 2019 - publications.aap.org
OBJECTIVE: To systematically review the cost-effectiveness of palivizumab prophylaxis
compared with no prophylaxis in infants< 24 months of age. DATA SOURCES: Medline …
compared with no prophylaxis in infants< 24 months of age. DATA SOURCES: Medline …
Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy
A Hiatt, N Bohorova, O Bohorov… - Proceedings of the …, 2014 - National Acad Sciences
Respiratory syncytial virus (RSV) can cause devastating lower respiratory tract infections in
preterm infants or when other serious health problems are present. Immunoprophylaxis with …
preterm infants or when other serious health problems are present. Immunoprophylaxis with …
Palivizumab prophylaxis for respiratory syncytial virus: examining the evidence around value
Respiratory syncytial virus (RSV) infection is the most common cause of lower respiratory
tract infection and the leading cause of hospitalization among young children, incurring high …
tract infection and the leading cause of hospitalization among young children, incurring high …
Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review
C Wegzyn, LK Toh, G Notario, S Biguenet… - Infectious diseases and …, 2014 - Springer
Introduction Lower respiratory tract infection (LRTI) is the leading cause of infant mortality
globally in post-neonatal infants (ie, 28–364 days of age). Respiratory syncytial virus (RSV) …
globally in post-neonatal infants (ie, 28–364 days of age). Respiratory syncytial virus (RSV) …
A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice
BA Paes, I Mitchell, A Banerji… - Canadian …, 2011 - Wiley Online Library
Respiratory syncytial virus (RSV) is a common infection in infancy, with nearly all children
affected by two years of age. Approximately 0.5% to 2.0% of all children are hospitalized …
affected by two years of age. Approximately 0.5% to 2.0% of all children are hospitalized …